A New Era of Treatment Options for Patients with Advanced Renal-Cell Cancer

Laura Wood,  RN, MSN, OCN

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

IWTI Best Practices in GU Navigation

A New Era of Treatment Options for Patients with Advanced Renal-Cell Cancer

Videos - Interview with the Innovators

Megan Price, MSN, APRN, FNP-C

Baylor Charles A. Sammons Cancer Center
Dallas, TX

Virginia Seery, MSN, RN, ANP-BC, AOCNP

Beth Israel Deaconess Medical Center
Boston, MA

Laura Wood, RN, MSN, OCN

Cleveland Clinic Taussig Cancer Center
Cleveland, OH

Combinations of agents have replaced sunitinib as first-line therapy for advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their best practices for helping patients get the most benefit out of combination therapy for their advanced renal-cell cancer diagnosis.